Old Web
English
Sign In
Acemap
>
authorDetail
>
Roy S. Herbst
Roy S. Herbst
University of Texas Health Science Center at Houston
Medicine
Lung cancer
Phases of clinical research
Erlotinib
Adenocarcinoma of the lung
5
Papers
302
Citations
0.01
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
How to Promote and Organize Clinical Research in Lung Cancer
2018
Fabrice Barlesi
J. Mazieres
Yang Zhou
Roy S. Herbst
Gérard Zalcman
Show All
Source
Cite
Save
Citations (0)
A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung
2010
Journal of Thoracic Oncology
Natasha B. Leighl
Luis E. Raez
Benjamin Besse
Peter Rosen
Fabrice Barlesi
Erminia Massarelli
Nashat Gabrail
Lowell L. Hart
Kathy S. Albain
Lloyd Berkowitz
O. Melnyk
Frances A. Shepherd
Lars Sternas
Judie Ackerman
Zhenming Shun
Vincent A. Miller
Roy S. Herbst
Show All
Source
Cite
Save
Citations (82)
Treatment of Advanced Non-Small Cell Lung Cancer: Second-line Therapy With Novel Agents
2008
Roy S. Herbst
Erminia Massarelli
Show All
Source
Cite
Save
Citations (0)
Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib- resistant adenocarcinoma of the lung (NSCLA)
2007
Journal of Clinical Oncology
E. Massarelli
Vincent A. Miller
Natasha B. Leighl
P J Rosen
Kathy S. Albain
Lowell L. Hart
O. Melnyk
L Sternås
J. Ackerman
Roy S. Herbst
Show All
Source
Cite
Save
Citations (41)
Mode of action of docetaxel - a basis for combination with novel anticancer agents
2003
Cancer Treatment Reviews
Roy S. Herbst
Fadlo R. Khuri
Show All
Source
Cite
Save
Citations (179)
1